1122 GMT - AstraZeneca's sales beat and key catalysts for 2025 outshine its core operating profit miss, Barclays analysts says in a note. The British pharma giant's oncology drugs beat sales expectations, driven by lung-cancer drug Tagrisso and breast-cancer treatment Lynparza, Barclays says. However, its core operating profit margin missed company-compiled consensus by 30%, they say. "We see AstraZeneca as having the strongest catalyst path in 2025 of any company in our coverage," the analysts say. Shares are up 5.1% at 116.92 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 06, 2025 06:22 ET (11:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。